13F Holdings
中文EN

BOLT Bolt Biotherapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1641281 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-51.3%
TTM net income YoY38.7%
TTM EPS YoY37.1%
Revenue 3-yr CAGR-29.4%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,098.0%
Net margin-1,034.4%
FCF margin—
EBITDA margin-1,068.0%

Returns

ROE-128.8%
ROA-52.0%
ROIC (approx.)-481.0%
Asset turnover0.05x

Leverage & solvency

Liabilities / assets75.9%
Debt / equity0.00x
Current ratio2.05x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.95x
Accruals ratio-2.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$7.70M$7.69M$7.88M$5.73M$1.26M
R&D expense$28.53M$57.47M$61.54M$73.12M$75.66M
SG&A expense$13.79M$18.46M$22.53M$22.93M$18.39M
Operating income-$36.11M-$73.05M-$76.20M-$90.32M-$92.79M
Pretax income-$33.38M-$63.12M———
Income tax$0$0$0$0$0
Net income-$33.38M-$63.12M-$69.20M-$88.10M-$98.59M
EBITDA-$34.82M-$71.27M-$74.34M-$88.66M-$91.59M
EPS (basic)-17.85-33.06-1.83-2.36-2.97
EPS (diluted)-17.85-33.06-1.83-2.36-2.97
Weighted avg. shares (diluted)1.87M1.91M37.81M37.36M33.20M
Balance sheet
Cash & equivalents$11.70M$7.21M$10.81M$9.24M$27.38M
Short-term investments$15.80M$40.12M$91.38M$159.64M$158.84M
Current assets$30.26M$50.81M$105.71M$172.75M$189.16M
PP&E, net$1.25M$3.14M$4.96M$6.45M$6.16M
Total assets$56.75M$99.63M$159.78M$227.81M$307.72M
Current liabilities$8.44M$15.86M$20.46M$23.12M$21.33M
Total liabilities$30.24M$42.43M$47.04M$56.30M$57.60M
Shareholders' equity$26.50M$57.20M$112.74M$171.51M$250.12M
Shares outstanding1.92M1.92M38.11M37.80M37.40M
Cash flow statement
Operating cash flow-$39.85M-$61.29M-$69.53M-$76.50M-$57.07M
Capital expenditure$72,000$41,000$206,000$1.95M$2.34M
Free cash flow-$39.92M-$61.33M-$69.73M-$78.46M-$59.40M
Investing cash flow$44.30M$57.58M$71.04M$57.86M-$232.20M
Financing cash flow$19,000$108,000$253,000$503,000$311.11M
Depreciation & amortization$1.29M$1.78M$1.85M$1.67M$1.19M
Stock-based compensation$2.78M$7.41M$9.22M$9.58M$8.50M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.